Detalhe da pesquisa
1.
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Lancet HIV
; 9(9): e638-e648, 2022 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36055295